Ginkgo Bioworks Holdings (DNA) is back in focus after reporting 2025 results that combined smaller losses and lower cash burn with a clear pivot toward robotics-powered autonomous labs and a planned biosecurity divestiture.
See our latest analysis for Ginkgo Bioworks Holdings.
The earnings release, biosecurity divestiture plan, and new autonomous lab contracts have coincided with heavy selling, including a 30.48% 1-day share price return decline and a 26.79% 7-day share price return decline. The 1-year total shareholder return of 18.08% and 3-year total shareholder return of 87.86% declines underline how pressure on expectations has built over time.
If this sharp move has you reassessing opportunities around robotics and lab automation, it could be a good time to scan 30 robotics and automation stocks for potential alternatives and comparables.
With revenue at US$170.16 million, a net loss of US$312.76 million, a share price at US$6.75, and a sizeable discount to the US$10 price target, is this selloff creating an entry point or simply reflecting expectations for future growth?
Most Popular Narrative: 32.5% Undervalued
Ginkgo Bioworks Holdings' most followed narrative pegs fair value at $10 per share, above the last close at $6.75. This frames the recent selloff against longer term earnings and margin ambitions.
The company's early achievement of $250 million in annual cost savings, coupled with a significant cash position ($474 million) and no bank debt, provides financial flexibility and a strong margin of safety to invest in future growth initiatives, which may enhance earnings and support sustainable profit margin improvement.
Curious how a loss making business, expected revenue headwinds, and future margin expansion are combined into one valuation story? The key is how analysts frame the earnings path, long run profitability, and the price multiple they believe the market will accept if that script plays out.
Result: Fair Value of $10 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still clear risks, including slower than hoped adoption of Ginkgo's automation and AI tools, as well as ongoing pressure from regulatory and geopolitical scrutiny.
Find out about the key risks to this Ginkgo Bioworks Holdings narrative.
Another lens on value
The narrative points to a fair value of $10 per share, yet the market is also pricing Ginkgo off revenue. At a P/S of 2.3x versus a fair ratio of 2x, and peers closer to 4.9x, the stock screens cheaper than many rivals but still slightly rich versus that fair ratio. Is that premium a cushion or an extra risk if expectations reset again?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
The mix of pressure and potential around Ginkgo can feel finely balanced, so it makes sense to move quickly, review the data for yourself, and weigh up the trade off between the company’s concerns and bright spots with 2 key rewards and 2 important warning signs.
Looking for more investment ideas?
If this has sharpened your focus on where to put fresh capital, do not stop at a single stock. Instead, widen your search with a few targeted screens.
- Zero in on value by checking companies that appear mispriced against their fundamentals using our 46 high quality undervalued stocks.
- Prioritise resilience by scanning businesses with stronger balance sheets through the solid balance sheet and fundamentals stocks screener (39 results).
- Hunt for off the radar opportunities by reviewing our screener containing 24 high quality undiscovered gems before other investors catch on.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com